Analysts’ Recent Ratings Changes for Stryker (SYK)

Several analysts have recently updated their ratings and price targets for Stryker (NYSE: SYK):

• 10/31/2024 – Stryker had its price target raised by analysts at Barclays PLC from $402.00 to $418.00. They now have an “overweight” rating on the stock.
• 10/31/2024 – Stryker had its price target raised by analysts at Citigroup Inc. from $406.00 to $411.00. They now have a “buy” rating on the stock.
• 10/30/2024 – Stryker had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $420.00 price target on the stock, up previously from $380.00.
• 10/30/2024 – Stryker had its price target raised by analysts at JPMorgan Chase & Co. from $375.00 to $420.00. They now have an “overweight” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at Wells Fargo & Company from $381.00 to $405.00. They now have an “overweight” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at Royal Bank of Canada from $386.00 to $400.00. They now have an “outperform” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at Evercore ISI from $380.00 to $384.00. They now have an “outperform” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at Robert W. Baird from $378.00 to $405.00. They now have an “outperform” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at UBS Group AG from $366.00 to $370.00. They now have a “neutral” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at Truist Financial Co. from $370.00 to $380.00. They now have a “hold” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at BTIG Research from $383.00 to $394.00. They now have a “buy” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at Canaccord Genuity Group Inc. from $360.00 to $400.00. They now have a “buy” rating on the stock.
• 10/30/2024 – Stryker had its price target raised by analysts at Needham & Company LLC from $393.00 to $409.00. They now have a “buy” rating on the stock.
• 10/14/2024 – Stryker had its price target raised by analysts at Truist Financial Co. from $345.00 to $370.00. They now have a “hold” rating on the stock.
• 10/14/2024 – Stryker had its price target raised by analysts at BTIG Research from $374.00 to $383.00. They now have a “buy” rating on the stock.
• 10/1/2024 – Stryker had its price target raised by analysts at Evercore ISI from $365.00 to $380.00. They now have an “outperform” rating on the stock.
• 10/1/2024 – Stryker was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 9/16/2024 – Stryker was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 9/10/2024 – Stryker had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $380.00 price target on the stock.
• 9/10/2024 – Stryker is now covered by analysts at Wolfe Research. They set an “outperform” rating and a $405.00 price target on the stock.

Stryker Price Performance

NYSE SYK traded down $0.84 during trading hours on Wednesday, hitting $369.02. 1,366,185 shares of the company’s stock traded hands, compared to its average volume of 1,257,470. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The firm’s 50-day moving average is $360.66 and its 200-day moving average is $344.95. Stryker Co. has a 52-week low of $266.93 and a 52-week high of $376.04. The company has a market capitalization of $140.68 billion, a PE ratio of 39.55, a PEG ratio of 2.77 and a beta of 0.91.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same quarter in the previous year, the firm earned $2.46 EPS. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. Equities analysts forecast that Stryker Co. will post 12.06 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Viju Menon sold 600 shares of Stryker stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares in the company, valued at approximately $3,219,495. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Stryker news, insider Viju Menon sold 600 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the transaction, the insider now owns 9,069 shares in the company, valued at $3,219,495. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP M Kathryn Fink sold 2,121 shares of the stock in a transaction on Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the completion of the sale, the vice president now owns 10,042 shares in the company, valued at approximately $3,715,540. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,068 shares of company stock valued at $3,693,972 over the last 90 days. 5.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Stryker

Institutional investors have recently added to or reduced their stakes in the business. Centennial Bank AR grew its position in Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after purchasing an additional 48 shares during the last quarter. Central Pacific Bank Trust Division purchased a new position in shares of Stryker during the first quarter worth about $39,000. Hara Capital LLC purchased a new position in shares of Stryker during the third quarter worth about $42,000. HBW Advisory Services LLC acquired a new position in Stryker in the 3rd quarter valued at about $42,000. Finally, Grove Bank & Trust lifted its position in Stryker by 84.8% during the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock worth $44,000 after acquiring an additional 56 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.